Cailin Conner

DocwireNews

Affecting upwards of 9 million adults in the US, gout is one of the most common forms of inflammatory arthritis. Patients with gout experience recurrent flares of joint pain and swelling, which can lead to joint damage and functional impairment if undertreated or not treated at all. It&rsquo;s also associated with other conditions, including chronic kidney disease.There has been ample research on gout, and there are effective and inexpensive medications to treat it; however, there has been <a href="https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(22)00110-7/fulltext" target="_blank" rel="noopener">research</a> published that just one in three individuals diagnosed with gout are prescribed preventative medications. Medicated treatment typically follows <a href="https://www.rheumatology.org/Practice-Quality/Clinical-Support/Clinical-Practice-Guidelines/Gout" target="_blank" rel="noopener">The American College of Rheumatology&rsquo;s (ACR) 2020 guidelines</a>, which involves using a treat-to-target (T2T) approach to lower serum urate (SU) levels in the blood. The target SU level has been previously defined as &lt;6.0 mg/dL, yet many individuals with gout have difficulty reaching this level without the aid of medications in conjunction with lifestyle changes.A retrospective observational study published in <a href="https://onlinelibrary.wiley.com/doi/10.1002/acr.25009" target="_blank" rel="noopener">Arthritis Care &amp; Research</a> utilized the ACR&rsquo;s Rheumatology Informatics System for Effectiveness (RISE) registry and assessed the use of a T2T approach among gout patients receiving long-term SU lowering therapy while being followed longitudinally by rheumatologists. The RISE registry, comprised of data collected during routine clinical care at participating rheumatology practices across the US, allowed the authors of the study to include 9560 patients in their analysis. The main outcomes measured included the proportions of patients with SU monitoring, who achieved the target SU level during the measurement year. Sociodemographic information, comorbidities, and health care utilization were used to determine factors associated with SU monitoring and achievement of target SU levels through the use of multilevel logistic regression.The mean age of the patients was 67.2 years, 73.5% were male, and 32.3% were non-White. Fifty-six percent had recorded at least one SU during the measurement year. Of these patients, 74% achieved the SU target level of &lt;6.0 mg/dL. Patients receiving long-term urate lowering therapy were significantly more likely to achieve target SU levels compared with those not receiving treatment. Multivariate analysis showed that non-white patients were slightly less likely to be tested or achieve a target SU.&ldquo;Routine monitoring of SU is a first step toward improving quality of care for patients with gout,&rdquo; the authors wrote.

Jordana Jampel

Brensocatib Shows Positive Results for Managing Bronchiectasis Symptoms

Pulmonology

Areef Ishani, MD

Joel M. Topf, MD, FACP

Kidney Stones With Chlorthalidone Versus Hydrochlorothiazide

NKF Spring Clinical Meetings 2025

MarkAlain Déry, DO

Eric Griggs, MD

Measles in America: An Ongoing Problem

Infectious Disease

Latest News

Target SU Levels in Gout Patients in the ACR’s RISE Registry

Nephrology Times

Affecting upwards of 9 million adults in the US, gout is one of the most common forms of inflammatory arthritis. Patients with gout experience recurrent flares of joint pain ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe